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Abstract 
Objective 
To evaluate the outcomes of robot-assisted partial nephrectomy (RAPN) in cystic tumours, 
analysing a large, multi-institutional, retrospective series of RAPN, as limited data are available 
about the outcome of RAPN in cystic tumours. 
Patients and Methods 
We evaluated 465 patients who received RAPN for either cystic or solid tumours from 2010 to 2013 
and included in the multi-institutional, retrospective Vattikuti Global Quality Initiative in Robotic 
Urologic Surgery (GQI-RUS) database. Univariable and multivariable linear and logistic regression 
models addressed the association of cystic tumours with perioperative outcomes. 
Results 
In all, 54 (12%) tumours were cystic. Cystic tumours were associated with significantly lower 
operative time (t −3.9; P < 0.001), once adjusted for the effect of covariates, whereas blood loss and 
warm ischaemia time were similar. Postoperative any grade complications were recorded in 66 solid 
(16%) and nine cystic (17%) tumours (P = 0.08). In multivariable analysis, cystic tumours were not 
associated with a significantly lower risk of any grade postoperative complications [odds ratio (OR) 
0.9; P = 0.8]. Similarly, presence of tumours with cystic features was not associated with a 
significantly different risk of high-grade postoperative complications (OR 2.2; P = 0.1). Prevalence 
of cancer histology and positive surgical margin rates were similar in cystic and solid tumours. 
Cystic tumours were not associated with significantly different postoperative estimated glomerular 
filtration rate (t 0.4; P = 0.7), once adjusted for the effect of covariates. 
Conclusions 
RAPN can be performed in cystic renal tumours with perioperative, pathological, and functional 
outcomes similar to those achievable in solid tumours. 
Introduction 
Partial nephrectomy (PN) is considered the standard surgical treatment for small renal masses [1, 2]. 
In the last decade, robot-assisted PN (RAPN) has gained in popularity and been increasingly 
applied, with convincing results [3, 4]. 
Up to 20% of the renal masses suitable for PN contain cystic components [5, 6]. Cystic lesions may 
represent a particular challenge during RAPN due to the risk of rupture of the cystic wall. The 
available literature on RAPN performed for cystic renal masses is indeed very limited. Recently, 
Akca et al. [7] reported the experience of a single tertiary USA referral centre reporting good 
outcomes for RAPN in cystic tumours, comparable to solid lesions. However, the paper reports the 
experience of a single, referral, high-volume centre expert in dealing with RAPN and the 
reproducibility of those findings is other centres has not been confirmed. Consequently, the purpose 
of the present study was to report outcomes of RAPN in a large, multi-institutional, retrospective 
series of RAPN. 
Patients and Methods 
The Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI-RUS) database is an 
Institutional Review Board-approved database including data of 10 worldwide centres. A 
computerised databank was generated for data transfer. After combining the data sets, reports were 
generated for each variable to identify data inconsistencies and other data integrity problems. 
Through regular communication with all sites, resolution of all identified anomalies was achieved 
before analysis. Before final analysis, the database was frozen, and the final data set was produced 
for the current analysis. 
The GQI-RUS database comprised 1 045 patients who underwent RAPN between 2010 and 2013 
for clinical N0M0 renal tumours. After exclusion of patients where the Preoperative Aspects and 
Dimensions Used for an Anatomical (PADUA)-score classification [8] was not available (580 
patients), the 465 remaining patients were the subjects of the present analysis. 
Charlson comorbidity index was adopted to report patient comorbidity [9]. The PADUA score was 
adopted to report anatomical characteristics of the renal tumour [8]. Renal function was assessed by 
calculating the estimated GFR (eGFR) using the modification of diet in renal disease formula [10]. 
Cystic renal masses were diagnosed on cross-sectional imaging (CT or MRI; Fig. 1). Surgery was 
performed by several surgeons according to the standard criteria for RAPN, i.e. complete resection 
of the tumour and a border of healthy parenchyma. Lymphadenectomy was not routinely 
performed. 
 
Figure 1.  
 Open in figure viewer 
CT scan of a 5-cm cystic renal mass, with irregular thickness and some calcification in cystic wall. 
Note contralateral healthy kidney, with regular excretion of the contrast in the renal pelvis. 
Pathological Evaluation 
All surgical specimens were processed according to standard pathological procedures at each 
institution. Tumours were staged according to the 2010 American Joint Committee on Cancer–
Union Internationale Contre le Cancer TNM classification [11]. Histological subtype was defined 
according to the Heidelberg classification [12]. Tumour grading was assessed according to the 
Fuhrman system [13]. Positive surgical margin (PSM) status was defined as the presence of 
malignant tissue on the inked surface of the tumour on final pathological assessment. 
Follow-up Regimen 
Patients were generally assessed every 3–6 months for the first year after RAPN, and annually 
thereafter. Follow-up consisted of a history, physical examination, routine blood work and serum 
chemistry studies, chest and abdominal imaging, as per urologist preference. 
Statistical Analysis 
The chi-square test was used to evaluate the association between categorical variables. Differences 
in variables with a continuous distribution across dichotomous categories were assessed using the 
Mann–Whitney U-test. Univariable and multivariable linear and logistic regression models 
addressed the association of cystic feature with operative time, warm ischaemia time (WIT), 
estimated blood loss (EBL), intraoperative and postoperative any grade and high-grade 
complications, pathological outcome (presence of malignant disease and PSM), and eGFR after 
RAPN. T statistics and odds ratios (ORs) with 95% CIs were used to report regression analyses. All 
multivariable regression analyses were adjusted for age, gender, Charlson comorbidity index, 
indication for RAPN, and PADUA-score risk group. Subgroup analyses were performed in the 
different PADUA-score risk groups adjusting for the other covariates. Statistical significance in this 
study was set as P ≤ 0.05. All reported P values are two-sided. Analyses were performed with SPSS 
vers 20.0 (SPSS Inc, Chicago, IL, USA). 
Results 
In all, 54 (12%) tumours were cystic. Table 1 shows the association between the presence of a 
cystic renal mass with clinical features in this cohort. Patient age, prevalence of imperative 
indication for RAPN, and PADUA-score risk group were significantly different in cystic and solid 
tumours (all P < 0.05). 
Table 1. Association of the presence of cystic tumours with clinical, intraoperative, postoperative 
and pathological characteristics of 465 patients treated with RAPN 
Variable All patients Cystic tumours Solid tumours P  
1. *Data missing in 34 cases (7%); †data missing in six cases (1.6%) of the 370 with RCC; 
‡
data missing in six cases (4.3%) of the 370 with RCC. 
Number of patients (%) 465 (100) 54 (12) 411 (88)   
Variable All patients Cystic tumours Solid tumours P  
Male gender, n (%) 317 (68.2) 36 (66.7) 281 (68.4) 0.801 
Median (IQR) 
Age, years 59 (50–67) 62 (54.7–71.2) 58 (49–66) 0.035 
Charlson comorbidity index 1 (0–3) 2 (0–3) 1 (0–3) 0.322 
Clinical tumour size, mm 32 (23–40) 34.5 (21–50.2) 32 (23–40) 0.184 
N (%) 
Imperative indication to RAPN, 12 (2.6) 4 (7.4) 8 (1.9) 0.017 
Symptoms at presentation 53 (11.4) 10 (18.5) 43 (10.5) 0.212 
Clinical T stage 
T1a 358 (77) 37 (68.5) 321 (78.1) 
0.185 
T1b 100 (21.5) 15 (27.8) 85 (20.7) 
T2a 3 (0.6) 1 (1.9) 2 (0.5) 
T2b 2 (0.4) 1 (1.9) 1 (0.2) 
T3 2 (0.4) 0 2 (0.5) 
PADUA-score risk group 
Low 214 (46) 13 (24.1) 201 (48.9) 
0.001 Intermediate 146 (31.4) 28 (51.9) 118 (28.7) 
High 105 (22.6) 13 (24.1) 92 (22.4) 
No clamping of the renal artery* 13 (3) 2 (4.1) 11 (2.8) 0.626 
Median (IQR) 
Operative time, min 150 (120–200) 120 (105–150) 160 (120–210) <0.001 
EBL, mL 100 (60–200) 150 (80–250) 100 (60–200) 0.482 
WIT, min 17 (13–21) 18 (13–20.5) 17 (13–21) 0.812 
N (%) 
Intraoperative complications 24 (5.2) 0 24 (5.8) 0.068 
Postoperative complications 
Grade 0 390 (83.9) 45 (83.3) 345 (83.9) 
0.077 
Grade 1 28 (6) 0 28 (6.8) 
Grade 2 24 (5.2) 3 (5.6) 21 (5.1) 
Grade 3 18 (3.9) 4 (7.4) 14 (3.4) 
Grade 4 3 (0.6) 1 (1.9) 2 (0.5) 
Grade 5 2 (0.4) 1 (1.9) 1 (0.2) 
Median (IQR) 
Length of stay, days 5 (4–6) 5 (4–7) 5 (4–6) 0.076 
Pathological tumour size, mm 30 (20–40) 29 (17–40) 30 (21–40) 0.651 
N (%) 
Histology 
Benign 95 (20.4) 11 (20.4) 84 (20.4) 
0.418 
Clear cell RCC 282 (60.6) 31 (57.4) 251 (61.1) 
Papillary RCC 56 (12) 10 (18.5) 46 (11.2) 
Chromophobe RCC 26 (5.6) 1 (1.9) 25 (6.1) 
Variable All patients Cystic tumours Solid tumours P  
Unclassified RCC 6 (1.3) 1 (1.9) 5 (1.2) 
Pathological T stage† 
T1a 274 (75.3) 33 (76.7) 241 (75.1) 
0.945 
T1b 60 (16.5) 6 (14) 54 (16.8) 
T2a 3 (0.8) 0 3 (0.9) 
T3 27 (4.1) 4 (9.3) 23 (7.2) 
Fuhrman nuclear grade‡ 
1 74 (20.9) 14 (33.3) 60 (19.2) 
0.127 
2 246 (69.5) 23 (54.8) 232 (71.5) 
3 32 (9) 5 (11.9) 27 (8.7) 
4 2 (0.6) 0 2 (0.6) 
PSM 21 (4.5) 4 (7.4) 17 (4.2) 0.281 
Median (IQR) eGFR, mL/min/1.73 m
2
 
Preoperative 81 (69–94) 79 (66–94) 81 (69–95) 0.362 
At follow-up 78 (64–87) 76 (65–80) 78 (63–88) 0.345 
Intraoperative Variables 
Cystic tumours were associated with significantly lower operative time (t −3.9; P < 0.001), once 
adjusted for the effect of covariates. Stratifying by PADUA score, such an association was evident 
in intermediate (t −3.1; P = 0.02), and high (t −2.2; P = 0.03) PADUA-score risk groups, but not in 
the low-risk category. Conversely, cystic tumours were not associated with differences in EBL and 
WIT, either in the full cohort or when stratifying by PADUA-score risk groups. There were no 
cases of cystic wall rupture. 
Postoperative Variables 
Postoperative complications of any grade were recorded in 66 solid (16%) and nine cystic (17%) 
tumours (P = 0.08). In univariable regression analysis, cystic tumours were not associated with a 
significantly different risk of any grade of postoperative complication (OR 1.1; P = 0.9). In 
multivariable analysis, presence of tumours with cystic features was not associated with a 
significantly lower risk of any grade postoperative complications (OR 0.9; P = 0.8) once adjusted 
for covariates. Also, stratifying by PADUA-score risk group, any correlation among cystic tumours 
and any grade of postoperative complications failed to be demonstrated. 
Grade 3 to 5 postoperative complications occurred in 17 solid (4%) and six cystic (11%) tumours (P 
= 0.03). In univariable regression analysis, cystic tumours were associated with a significantly 
higher risk of high-grade postoperative complications (OR 2.9; P = 0.03). In multivariable analysis, 
presence of tumours with cystic features was not associated with a significantly different risk of 
high-grade postoperative complications (OR 2.2; P = 0.1). Also stratifying by PADUA-score risk 
group, any correlation among cystic tumours and high-grade postoperative complications failed to 
be demonstrated. 
Pathological Outcomes 
The prevalence of RCC was similar in both groups (79.6% vs 79.6%; P = 0.991). In univariable 
regression analysis, cystic tumours were not associated with a significantly different risk of a 
malignant histology (OR 1.0; P = 0.99). In multivariable analysis, presence of tumours with cystic 
features was not associated with a significantly higher risk of malignant histology (OR 0.8; P = 
0.7). Also stratifying by PADUA-score risk group, any correlation among cystic tumours and 
malignant histology failed to be demonstrated. 
PSMs were identified in 17 of 409 (4.2%) solid RCCs and in four of 54 (7.4%) RCCs with a cystic 
component (P = 0.281). In univariable regression analysis, cystic tumours were not associated with 
a significantly higher risk of PSM (OR 1.0; P = 0.99). Similarly, in multivariable analysis, cystic 
tumours were not associated with a significantly higher risk of PSM (OR 1.5; P = 0.5). Similar 
results were seen when stratifying by PADUA-score risk group. 
Postoperative Renal Function 
The median (interquartile range, IQR) baseline eGFR was 79 (66–94) and 81 (69–95) mL/min/1.73 
m
2
 in cystic and solid tumours, respectively (P = 0.362). The median (IQR) follow-up duration was 
10 (3–24) and 6 (3–19) months in the cystic and solid tumour groups, respectively (P = 0.364). At 
follow-up, the median (IQR) postoperative eGFR was 76 (65–80) mL/min/1.73 m2 in those with 
cystic tumours (P = 0.878) and 78 (63–88) mL/min/1.73 m2 in those with solid tumours (P = 0.345). 
The cystic tumours were not associated with significantly different postoperative eGFR (t 0.4; P = 
0.7), once adjusted for the effect of covariates. Also, when stratifying by PADUA score, no 
difference was seen in any risk group. 
Oncological Outcome 
At follow-up, we identified one local recurrence (1.9%) in the cystic group and 10 (1.8%) in the 
solid tumour group (P = 0.425). None of the patients with PSM had recurred by the most recent 
follow-up. The limited number of events precludes further predictive analysis. 
Discussion 
In the present study, we analysed the outcomes of RAPN in cystic renal masses, evaluating the 
GQI-RUS database, a large retrospective database of RAPN performed in several institutions 
worldwide. We demonstrated that, even in this special setting of patients; RAPN is associated with 
favourable intra- and perioperative outcomes, which indeed were mostly similar to those achievable 
in solid tumours for most of the intraoperative parameters, postoperative complications, 
pathological and functional results. 
Although up to 20% of the tumours included in PN series have cystic components [5, 6], the 
peculiarities of RAPN in cystic lesions have undergone limited evaluation in the currently available 
literature. Specifically, due to the risk of cystic wall rupture during tumour resection and the 
subsequent risk of local tumour spillage, handling of cystic tumours may require special care and 
skills. Specifically, Akca et al. [7] reported on 55 cystic tumours treated with RAPN at the 
Cleveland Clinic Foundation from 2007 and 2014. The perioperative and postoperative results of 
RAPN in that setting were compared with a contemporary matched cohort of patients treated with 
RAPN at the same centre for solid tumours. Finally, the authors showed that intraoperative 
variables (operating time, EBL, WIT, and complications), postoperative complications, and eGFR 
decline were similar in the two groups [7]. Notably, the prevalence of RCC was higher in the solid 
tumour group, due to the presence of 18 benign cysts. Although large, and homogeneous, the above 
mentioned results represent the outcome of RAPN as performed by three high-volume surgeons at a 
tertiary referral centre. For that reason, we decided to analyse our multi-institutional RAPN 
database to assess the outcome of RAPN in cystic lesions. We have shown that RAPN in these 
patients was associated with outcomes that were similar to those of solid tumours. With the 
exception of operating time, which was indeed slightly shorter in cystic lesions once adjusted for 
covariates, all the other intraoperative (EBL, WIT, complications), postoperative (any grade 
complications and high-grade complications), pathological features (prevalence of malignant 
histology and PSMs), and functional outcomes were overlapping in cystic and solid lesions. 
Notably, we stratified our present results according to the anatomical characteristics of the tumours, 
as assessed by the PADUA score [8], in order to further assess the impact of the cystic component 
together with the other anatomical characteristics of the renal mass. Taken together, the data 
corroborate the concept that RAPN can be a safe and appropriate treatment in cases of cystic lesions 
whenever PN is indicated for surgeons with adequate experience in RAPN. Such findings are of 
special relevance due to the multi-institutional, multi-surgeon nature of the present series, 
suggesting reproducibility of the above mentioned findings in the hands of several surgeons and 
also outside of high-volume centres. 
There are several limitations to our present study. First and foremost are the limitations inherent to 
retrospective analyses. Secondly, due to the lack of data on PADUA-score classification in several 
patients included in our database, we were obliged to limit the analyses to <50% of the cases 
included in the database. Consequently, the number of patients with cystic tumours was relatively 
low, which could have made some of our statistical analyses underpowered. However, we found 
that the relevance of the study would have been much higher stratifying all the outcomes by the 
anatomical tumour characteristics, as expressed by the PADUA score. Thirdly, the population in the 
present study underwent RAPN by multiple surgeons, and specimens were evaluated by multiple 
pathologists without slide review. However, all surgeons operated at selected centres with 
significant experience in robotic surgery, which might increase the external validity of the data, 
compared with the single-centre setting. Fourth, data on Bosniak classification was not available in 
our database and radiological revision of the preoperative imaging was not possible. Revision of the 
preoperative imaging could have minimised the risk of misdiagnosis of macroscopic poorly 
enhancing lesions and/or macroscopic tumour necrosis as cystic lesions, risk which indeed is 
present in our analyses. Finally, the limited number of disease recurrence available at the present 
follow-up prevented us from assessing the oncological efficacy of RAPN in cystic renal tumours. 
In conclusion, the present analysis suggests that RAPN can be performed for cystic renal tumour 
with perioperative, pathological, and functional outcomes similar to those achievable in solid 
tumours. Consequently, cystic lesions should not represent a contraindication for RAPN. 
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